--- title: "Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/297789167.md" description: "Halozyme Therapeutics (Nasdaq: HALO) announced that CEO Dr. Helen Torley and CFO Darren Snellgrove will participate in three investor conferences in September 2026. Events include the Wells Fargo Healthcare Conference on Sept 9, Morgan Stanley Global Healthcare Conference on Sept 15, and H.C. Wainwright Investment Conference on Sept 16. Presentations will feature fireside chats and one-on-one meetings, with audio webcasts available via the company's Investor Relations website." datetime: "2026-09-02T04:30:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297789167.md) - [en](https://longbridge.com/en/news/297789167.md) - [zh-HK](https://longbridge.com/zh-HK/news/297789167.md) generator: "portal-rs" --- # Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News Halozyme (HALO) will participate in three upcoming investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings with its President and CEO and CFO. , /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, September 9, 2026 Presentation Time: 12:45pm PT / 3:45pm ET Event: Morgan Stanley 24th Annual Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: Tuesday, September 15, 2026 Presentation Time: 4:45am PT / 7:45am ET Event: H.C. Wainwright 28th Annual Global Investment Conference Format: Fireside Chat and 1x1 Meetings Date: Wednesday, September 16, 2026 Presentation Time: 7:00am PT / 10:00am ET A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. **About Halozyme** Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics. Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility. **Contacts:** Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 tbui@halozyme.com Sydney Charlton Teneo 917-972-8407 sydney.charlton@teneo.com SOURCE Halozyme Therapeutics, Inc. ### Related Stocks - [HALO.US](https://longbridge.com/en/quote/HALO.US.md) - [WFC.US](https://longbridge.com/en/quote/WFC.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [4502.JP](https://longbridge.com/en/quote/4502.JP.md) - [TAK.US](https://longbridge.com/en/quote/TAK.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [4519.JP](https://longbridge.com/en/quote/4519.JP.md) - [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md) - [ABOS.US](https://longbridge.com/en/quote/ABOS.US.md) - [MRUS.US](https://longbridge.com/en/quote/MRUS.US.md) - [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md) - [INCY.US](https://longbridge.com/en/quote/INCY.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [VTRS.US](https://longbridge.com/en/quote/VTRS.US.md) - [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md) - [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md) - [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md) - [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md) - [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md) - [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) ## Related News & Research - [Talon Private Wealth LLC Invests $839,000 in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/298775197.md) - [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md) - [LEADSCALE® launches LEADSCALE ONEOne team, One Platform, One Business Day](https://longbridge.com/en/news/298624039.md) - [TECH ENTREPRENEURS MEARA BELKIN ANNOUNCE FIRST EVER PLATFORM INTEGRATING CYBER INSURANCE, SECURITY AND IT SERVICES](https://longbridge.com/en/news/298919661.md) - [One Solution S.A. Invests in Fitness Equipment to Boost Lease Income](https://longbridge.com/en/news/299086448.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**